MacroGenics, Inc., a clinical-stage biopharmaceutical company, will be receiving a $24.5 million regulatory milestone payment from Sanofi after the U.S. Food and Drug Administration's accelerated approval of TZIELD® (teplizumab-mzwv). This approval is for delaying the decline in endogenous insulin production in children aged 8 to 17 years newly diagnosed with stage 3 type 1 diabetes (T1D). The approval marks the expansion of TZIELD's potential as a disease-modifying therapy for type 1 diabetes.